Identification of Bone Metastatic and Prognostic Alternative Splicing Signatures in Prostate Adenocarcinoma

[1]  C. Shao,et al.  Widespread Alternative Splicing Changes in Metastatic Breast Cancer Cells , 2021, Cells.

[2]  O. Elemento,et al.  Clinical features of neuroendocrine prostate cancer. , 2019, European journal of cancer.

[3]  Mohammad Hossein Khosravi,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 , 2019, JAMA oncology.

[4]  Peihong Wu,et al.  Alternative splicing events are prognostic in hepatocellular carcinoma , 2019, Aging.

[5]  P. Barata,et al.  Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or… , 2019, Cancer.

[6]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[7]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[8]  E. Thompson,et al.  The phosphorylation status of PIP5K1C at serine 448 can be predictive for invasive ductal carcinoma of the breast , 2018, Oncotarget.

[9]  N. Cho,et al.  HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer , 2018, AntiCancer Research.

[10]  E. Crawford,et al.  Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations , 2018, Prostate Cancer and Prostatic Diseases.

[11]  Herng‐Ching Lin,et al.  Alzheimer’s disease is associated with prostate cancer: a population-based study , 2018, Oncotarget.

[12]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[13]  Rebeca D Martínez-Contreras,et al.  Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools , 2017, Genes.

[14]  Adam Godzik,et al.  The Functional Impact of Alternative Splicing in Cancer. , 2017, Cell reports.

[15]  R. Aebersold,et al.  Impact of Alternative Splicing on the Human Proteome , 2017, Cell Reports.

[16]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[17]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[18]  K. Nead,et al.  Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis , 2017, Prostate Cancer and Prostatic Diseases.

[19]  B. Cullen,et al.  Update on Alzheimer's Disease Therapy and Prevention Strategies. , 2017, Annual review of medicine.

[20]  A. Zoubeidi,et al.  Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer , 2016, Scientific Reports.

[21]  Charles G. Drake,et al.  Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer , 2016, Oncotarget.

[22]  Alzheimer’s Association,et al.  2016 Alzheimer's disease facts and figures , 2016, Alzheimer's & Dementia.

[23]  L. Shkreta,et al.  Defective control of pre–messenger RNA splicing in human disease , 2016, The Journal of cell biology.

[24]  Robert Brown,et al.  TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..

[25]  F. Montorsi,et al.  Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. , 2015, European urology.

[26]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[27]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[28]  Caterina Marchiò,et al.  SF3B1 mutations constitute a novel therapeutic target in breast cancer , 2014, The Journal of pathology.

[29]  Qingwen Xu,et al.  Targeting Type Iγ Phosphatidylinositol Phosphate Kinase Inhibits Breast Cancer Metastasis , 2014, Oncogene.

[30]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[31]  D. Bates,et al.  Hallmarks of alternative splicing in cancer , 2014, Oncogene.

[32]  H. Jim,et al.  Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis , 2014, Supportive Care in Cancer.

[33]  R. Bergan,et al.  Heat shock protein 27 regulates human prostate cancer cell motility and metastatic progression , 2014, Oncotarget.

[34]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[35]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[36]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[37]  D M Berney,et al.  Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer , 2012, Prostate Cancer and Prostatic Diseases.

[38]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[39]  John A. Calarco,et al.  Emerging Roles of Alternative Pre-mRNA Splicing Regulation in Neuronal Development and Function , 2012, Front. Neurosci..

[40]  S. Leung,et al.  Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer , 2010, Breast Cancer Research.

[41]  Francesco Piva,et al.  SpliceAid: a database of experimental RNA target motifs bound by splicing proteins in humans , 2009, Bioinform..

[42]  J. Goodwin,et al.  Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care. , 2008, Archives of internal medicine.

[43]  C. Nelson,et al.  Cognitive effects of hormone therapy in men with prostate cancer , 2008, Cancer.

[44]  Yue Sun,et al.  Type Iγ phosphatidylinositol phosphate kinase is required for EGF-stimulated directional cell migration , 2007, The Journal of cell biology.

[45]  Boris Hadaschik,et al.  The role of stress proteins in prostate cancer. , 2007, Current genomics.

[46]  R. Bergan,et al.  MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer , 2006, Oncogene.

[47]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[48]  G. Williams,et al.  Staging of prostatic carcinoma with radionuclide bone scintigraphy and lymphography. , 1987, The British journal of radiology.